Department of Human Genetics, Radboud university medical center, Nijmegen, the Netherlands.
Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.
Eur J Hum Genet. 2023 Jun;31(6):654-662. doi: 10.1038/s41431-023-01312-0. Epub 2023 Feb 13.
Various groups of neurological disorders, including movement disorders and neuromuscular diseases, are clinically and genetically heterogeneous. Diagnostic panel-based exome sequencing is a routine test for these disorders. Despite the success rates of exome sequencing, it results in the detection of causative sequence variants in 'only' 25-30% of cases. Copy number variants (CNVs), i.e. deletion or duplications, explain 10-20% of individuals with multisystemic phenotypes, such as co-existing intellectual disability, but may also have a role in disorders affecting a single system (organ), like neurological disorders with normal intelligence. In this study, CNVs were extracted from clinical exome sequencing reports of 4800 probands primarily with a movement disorder, myopathy or neuropathy. In 88 (~2%) probands, phenotype-matching CNVs were detected, representing ~7% of genetically confirmed cases. CNVs varied from involvement of over 100 genes to single exons and explained X-linked, autosomal dominant, or - recessive disorders, the latter due to either a homozygous CNV or a compound heterozygous CNV with a sequence variant on the other allele. CNVs were detected affecting genes where deletions or duplications are established as a common mechanism, like PRKN (in Parkinson's disease), DMD (in Duchenne muscular dystrophy) and PMP22 (in neuropathies), but also genes in which no intragenic CNVs have been reported to date. Analysis of CNVs as part of panel-based exome sequencing for genetically heterogeneous neurological diseases provides an additional diagnostic yield of ~2% without extra laboratory costs. Therefore it is recommended to perform CNV analysis for movement disorders, muscle disease, neuropathies, or any other single-system disorder.
各种神经紊乱疾病群体,包括运动障碍和神经肌肉疾病,在临床上和遗传学上都是异质的。基于诊断小组的外显子组测序是这些疾病的常规测试。尽管外显子组测序的成功率很高,但它只能在“仅”25-30%的病例中检测到致病序列变异。拷贝数变异(CNVs),即缺失或重复,解释了 10-20%具有多系统表型的个体,如共存智力障碍,但也可能在影响单一系统(器官)的疾病中发挥作用,如智力正常的神经紊乱。在这项研究中,从主要患有运动障碍、肌病或神经病的 4800 名先证者的临床外显子组测序报告中提取了 CNVs。在 88 名(约 2%)先证者中,检测到了表型匹配的 CNVs,占基因确诊病例的约 7%。CNVs 从涉及 100 多个基因到单个外显子不等,解释了 X 连锁、常染色体显性或隐性疾病,后者是由于纯合 CNV 或另一个等位基因上的序列变异导致的复合杂合 CNV。检测到的 CNVs 影响了一些基因,这些基因的缺失或重复是一种常见的机制,如 PRKN(在帕金森病中)、DMD(在杜氏肌营养不良症中)和 PMP22(在神经病变中),但也影响了一些目前尚未报道其基因内 CNVs 的基因。作为基于小组的外显子组测序的一部分,对遗传异质性神经疾病进行 CNV 分析,无需额外的实验室成本,可额外提供约 2%的诊断收益。因此,建议对运动障碍、肌肉疾病、神经病变或任何其他单一系统疾病进行 CNV 分析。